Biomarkers in Glioma Diagnosis and Prognosis

Gliomas represent a diverse group of primary brain tumours arising from glial cells and range in aggressiveness from low-grade astrocytomas to highly malignant glioblastoma. Accurate diagnosis and prognostication depend increasingly on molecular and cellular biomarkers that complement histopathology. Tissue markers such as glial fibrillary acidic protein variants, vascular endothelial growth factor A and chitinase-3-like protein 1 now inform tumour classification, grading and potential treatment sensitivity. Liquid biopsies in blood, cerebrospinal fluid or urine are being developed to detect circulating proteins, nucleic acids or vesicles that reflect tumour burden, invasiveness and microenvironmental interactions. Reliable biomarkers are essential for stratifying patients, predicting survival, monitoring response to therapies—including anti-angiogenic agents—and guiding personalised interventions. Integration of high-throughput proteomic and transcriptomic profiling with robust analytical methods has expanded the repertoire of candidate markers while improving sensitivity and specificity. Continued validation across clinical cohorts worldwide aims to establish panels that can be readily translated into clinical workflows, reducing reliance on invasive sampling and enabling earlier detection of recurrence or progression. Given the global burden of glioma and its poor prognosis in high-grade cases, advances in biomarker discovery and application hold promise for improved outcomes and therapeutic precision.

Research from Nature Portfolio

Recent studies have demonstrated the feasibility of non-invasive biomarker fingerprinting by analysing urinary protein patterns in patients with central nervous system tumours. Distinct sets of urinary proteins have been shown to discriminate tumour patients from controls with high sensitivity and specificity, suggesting a path towards routine urine-based screening and follow-up. In parallel, investigation of glial fibrillary acidic protein splice variants has revealed that the balance between canonical and delta isoforms modulates glioma cell migration within brain tissue. Depletion of the alpha isoform increases directed invasion into parenchyma, whereas loss of the delta isoform generates random cell motility. These findings highlight that isoform ratios not only reflect tumour aggressiveness but may serve as dynamic indicators of invasive potential and prognosis.

Biomarkers in Glioma Diagnosis and Prognosis publication trend

The graph below shows the total number of articles in biomarkers in glioma diagnosis and prognosis across all publications each year (not limited to Nature Index journals).

Technical terms

Biomarker: A measurable molecule or cellular feature indicative of a physiological or pathological process.

Glioma: A tumour originating from glial cells within the central nervous system.

Glioblastoma: The most aggressive and lethal grade of glioma, characterised by rapid growth and invasiveness.

Liquid biopsy: A non-invasive test to detect tumour-derived components such as proteins or nucleic acids in body fluids.

Isoform: A variant form of a protein arising through alternative splicing or post-translational modifications.

GFAP: Glial fibrillary acidic protein, an intermediate filament protein expressed by astrocytic cells.

VEGFA: Vascular endothelial growth factor A, a signalling protein that promotes angiogenesis.

YKL-40: Chitinase-3-like protein 1, an inflammatory glycoprotein linked to tumour progression and immune modulation.

References

1. Importance of GFAP isoform‐specific analyses in astrocytoma. Glia (2019).
2. High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers (2023).
3. High CHI3L1 expression is associated with glioma patient survival. Diagnostic Pathology (2016).
4. Disease specific urinary biomarkers in the central nervous system. Scientific Reports (2023).
5. GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence. Scientific Reports (2022).
6. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Frontiers in Oncology (2020).